BR112014010708B1 - compostos, processo para a preparação de um composto, usos de um composto e medicamento compreendendo um composto - Google Patents

compostos, processo para a preparação de um composto, usos de um composto e medicamento compreendendo um composto Download PDF

Info

Publication number
BR112014010708B1
BR112014010708B1 BR112014010708-4A BR112014010708A BR112014010708B1 BR 112014010708 B1 BR112014010708 B1 BR 112014010708B1 BR 112014010708 A BR112014010708 A BR 112014010708A BR 112014010708 B1 BR112014010708 B1 BR 112014010708B1
Authority
BR
Brazil
Prior art keywords
compound
acute
compounds
formula
salts
Prior art date
Application number
BR112014010708-4A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014010708A2 (pt
Inventor
Nils Griebenow
Frank Wunder
Ingo Flamme
Johannes Kobberling
Hans-Georg Lerchen
Rudolf Schohe-Loop
Sven Wittrock
Maria Kollnberger
Gorden Redlich
Andreas Knorr
July Marley
Iain Pritchard
Original Assignee
Bayer Pharma Aktiengesellschaft
Bayer Intellectual Property Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft, Bayer Intellectual Property Gmbh filed Critical Bayer Pharma Aktiengesellschaft
Publication of BR112014010708A2 publication Critical patent/BR112014010708A2/pt
Publication of BR112014010708B1 publication Critical patent/BR112014010708B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
BR112014010708-4A 2011-11-03 2012-10-30 compostos, processo para a preparação de um composto, usos de um composto e medicamento compreendendo um composto BR112014010708B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11187735.3 2011-11-03
EP11187735 2011-11-03
PCT/EP2012/071507 WO2013064508A1 (en) 2011-11-03 2012-10-30 Polyethylene glycol based prodrug of adrenomedullin and use thereof

Publications (2)

Publication Number Publication Date
BR112014010708A2 BR112014010708A2 (pt) 2017-04-25
BR112014010708B1 true BR112014010708B1 (pt) 2021-03-02

Family

ID=47146369

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010708-4A BR112014010708B1 (pt) 2011-11-03 2012-10-30 compostos, processo para a preparação de um composto, usos de um composto e medicamento compreendendo um composto

Country Status (45)

Country Link
US (3) US9603936B2 (cg-RX-API-DMAC7.html)
EP (2) EP2773376B1 (cg-RX-API-DMAC7.html)
JP (2) JP5995984B2 (cg-RX-API-DMAC7.html)
KR (2) KR101965467B1 (cg-RX-API-DMAC7.html)
CN (2) CN103998063B (cg-RX-API-DMAC7.html)
AR (2) AR088582A1 (cg-RX-API-DMAC7.html)
AU (2) AU2012331244B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014010708B1 (cg-RX-API-DMAC7.html)
CA (1) CA2854134C (cg-RX-API-DMAC7.html)
CL (1) CL2014000948A1 (cg-RX-API-DMAC7.html)
CO (1) CO7020863A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140184A (cg-RX-API-DMAC7.html)
CU (1) CU24184B1 (cg-RX-API-DMAC7.html)
CY (2) CY1117354T1 (cg-RX-API-DMAC7.html)
DK (2) DK3075395T3 (cg-RX-API-DMAC7.html)
DO (2) DOP2014000078A (cg-RX-API-DMAC7.html)
EA (2) EA025631B1 (cg-RX-API-DMAC7.html)
EC (2) ECSP14013326A (cg-RX-API-DMAC7.html)
ES (2) ES2568063T3 (cg-RX-API-DMAC7.html)
GT (1) GT201400085A (cg-RX-API-DMAC7.html)
HR (2) HRP20160285T1 (cg-RX-API-DMAC7.html)
HU (2) HUE027333T2 (cg-RX-API-DMAC7.html)
IL (3) IL232037B (cg-RX-API-DMAC7.html)
IN (1) IN2014CN03290A (cg-RX-API-DMAC7.html)
JO (2) JOP20190001B1 (cg-RX-API-DMAC7.html)
LT (1) LT3075395T (cg-RX-API-DMAC7.html)
MA (1) MA35618B1 (cg-RX-API-DMAC7.html)
ME (1) ME02379B (cg-RX-API-DMAC7.html)
MX (2) MX361287B (cg-RX-API-DMAC7.html)
MY (2) MY173372A (cg-RX-API-DMAC7.html)
NO (1) NO3075395T3 (cg-RX-API-DMAC7.html)
PE (2) PE20141219A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014500998A1 (cg-RX-API-DMAC7.html)
PL (2) PL3075395T3 (cg-RX-API-DMAC7.html)
PT (1) PT3075395T (cg-RX-API-DMAC7.html)
RS (2) RS54623B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201607516SA (cg-RX-API-DMAC7.html)
SI (2) SI3075395T1 (cg-RX-API-DMAC7.html)
TN (1) TN2014000185A1 (cg-RX-API-DMAC7.html)
TR (1) TR201802124T4 (cg-RX-API-DMAC7.html)
TW (2) TWI653051B (cg-RX-API-DMAC7.html)
UA (1) UA111098C2 (cg-RX-API-DMAC7.html)
UY (2) UY34419A (cg-RX-API-DMAC7.html)
WO (1) WO2013064508A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201600434B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014004953A (es) * 2011-11-03 2014-05-28 Bayer Ip Gmbh Ligadores basados en tirosina para la conexion desprendible de peptidos.
EP2896400A1 (en) * 2014-01-17 2015-07-22 Université Catholique De Louvain Method for increasing the bioavailability of inhaled compounds
WO2015141819A1 (ja) * 2014-03-20 2015-09-24 国立大学法人宮崎大学 長時間作用型アドレノメデュリン誘導体
AP2017009826A0 (en) * 2014-09-26 2017-03-31 Bayer Pharma AG Stabilized adrenomedullin derivatives and use thereof
CN114805540A (zh) * 2015-09-18 2022-07-29 国立大学法人宫崎大学 长效肾上腺髓质素衍生物
CN110678550B (zh) 2017-03-29 2023-11-14 国立大学法人宫崎大学 长效肾上腺髓质素衍生物
GB201707938D0 (en) * 2017-05-17 2017-06-28 Univ Sheffield Compounds
EP3986918A1 (en) 2019-06-18 2022-04-27 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use
CN115175703A (zh) * 2019-09-21 2022-10-11 艾夏卡法国有限公司 寡肽修饰的聚（β-氨基酯）的无DMSO合成及其在纳米颗粒递送系统中的应用
JP7498882B2 (ja) * 2019-12-05 2024-06-13 国立大学法人 宮崎大学 異常タンパク質蓄積性神経変性疾患の治療剤
US20230149553A1 (en) 2020-04-03 2023-05-18 Bayer Aktiengesellschaft Liquid pharmaceutical formulations polyethylene glycol-based prodrugs of adrenomedullin and use
JOP20220251A1 (ar) * 2020-04-03 2023-01-30 Bayer Ag تركيبات صيدلانية سائلة من عقاقير أولية أساسها متعدد إثيلين غليكول من أدرينوميدولين واستخدامها
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
CN112457218B (zh) * 2020-11-05 2022-08-09 宁夏医科大学 2,4-二氨基丁酸衍生物的合成方法
JP2024531394A (ja) 2021-08-20 2024-08-29 バイエル アクチェンゲゼルシャフト ペグ化アドレノメデュリンを調製する方法、その中間体およびその使用
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
IL318992A (en) 2022-05-02 2025-04-01 Precirix N V Cancer treatment through advance directives
WO2025133225A1 (en) 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Pharmaceutical combination of peptide-gly and peptidylglycine alpha-amidating monooxygenase (pam)
WO2025133215A1 (en) 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Use of inactive adrenomedullin precursor for therapeutic purposes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5020040A (en) * 1987-06-24 1991-05-28 Digital Equipment Corporation Overwriting system for magneto-optical recording with self timing track
US4812590A (en) 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
CA2292902C (en) 1999-12-24 2012-12-18 Alain Cadieux Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US20050271615A1 (en) 2002-08-30 2005-12-08 Doron Shabat Self-immolative dendrimers releasing many active moieties upon a single activating event
EP1560599A1 (en) 2002-11-14 2005-08-10 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
EP1646813B1 (en) 2003-07-23 2013-06-12 PPG Industries Ohio, Inc. Composite seal and window assembly
AU2005232371B2 (en) 2004-03-23 2010-10-14 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
WO2005116065A1 (en) 2004-05-24 2005-12-08 Institut De Cardiologie De Montréal Labelled adrenomedullin derivatives and their use for imaging and therapy
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8273325B2 (en) * 2006-12-20 2012-09-25 Ge Healthcare As Contrast agents
EP2155781B1 (en) 2007-05-11 2013-03-13 Institut de Cardiologie de Montréal Labelled adrenomedullin derivatives and their use for imaging and therapy.
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
MX2014004953A (es) * 2011-11-03 2014-05-28 Bayer Ip Gmbh Ligadores basados en tirosina para la conexion desprendible de peptidos.

Also Published As

Publication number Publication date
ES2659195T3 (es) 2018-03-14
US20160367636A1 (en) 2016-12-22
SI2773376T1 (sl) 2016-05-31
IL258229B (en) 2020-02-27
MY194197A (en) 2022-11-21
KR20150000462A (ko) 2015-01-02
ME02379B (me) 2016-06-20
DOP2018000203A (es) 2018-10-15
SG11201400924TA (en) 2014-09-26
HK1246147A1 (zh) 2018-09-07
CR20140184A (es) 2014-05-27
LT3075395T (lt) 2018-02-26
ES2568063T3 (es) 2016-04-27
GT201400085A (es) 2015-03-05
US9603936B2 (en) 2017-03-28
CN103998063A (zh) 2014-08-20
MX361287B (es) 2018-12-03
TN2014000185A1 (en) 2015-09-30
HRP20180319T1 (hr) 2018-03-23
UY34419A (es) 2013-05-31
AR088582A1 (es) 2014-06-18
IL232037B (en) 2018-12-31
US9649363B2 (en) 2017-05-16
CO7020863A2 (es) 2014-08-11
SI3075395T1 (en) 2018-03-30
AU2017203423A1 (en) 2017-06-08
PL2773376T3 (pl) 2016-07-29
JOP20190001B1 (ar) 2022-03-14
CN107412740A (zh) 2017-12-01
HRP20160285T1 (hr) 2016-04-22
IL252281B (en) 2021-01-31
JP5995984B2 (ja) 2016-09-21
EP2773376A1 (en) 2014-09-10
MX2014004384A (es) 2014-04-30
PH12014500998A1 (en) 2014-06-09
CN107412740B (zh) 2021-02-09
CU24184B1 (es) 2016-07-29
RS56819B1 (sr) 2018-04-30
AU2012331244A1 (en) 2014-04-17
EA201600495A1 (ru) 2016-10-31
EA029410B1 (ru) 2018-03-30
NZ714621A (en) 2017-10-27
MA35618B1 (fr) 2014-11-01
EP3075395B1 (en) 2017-11-22
ECSP18071104A (es) 2018-10-31
UY37922A (es) 2018-11-30
IL252281A0 (en) 2017-08-31
NZ622997A (en) 2015-12-24
TR201802124T4 (tr) 2018-03-21
DK2773376T3 (en) 2016-04-18
BR112014010708A2 (pt) 2017-04-25
JO3385B1 (ar) 2019-03-13
IN2014CN03290A (cg-RX-API-DMAC7.html) 2015-07-03
AR113830A2 (es) 2020-06-17
NO3075395T3 (cg-RX-API-DMAC7.html) 2018-04-21
CA2854134C (en) 2020-04-21
CU20140051A7 (es) 2014-10-02
TW201332573A (zh) 2013-08-16
KR101965467B1 (ko) 2019-04-03
US10035818B2 (en) 2018-07-31
ZA201600434B (en) 2017-05-31
AU2012331244B2 (en) 2017-06-15
US20140287984A1 (en) 2014-09-25
TW201720467A (zh) 2017-06-16
CY1117354T1 (el) 2017-04-26
IL232037A0 (en) 2014-05-28
US20170204137A1 (en) 2017-07-20
ECSP14013326A (es) 2014-05-31
KR102004668B1 (ko) 2019-07-26
PE20181493A1 (es) 2018-09-18
CL2014000948A1 (es) 2014-09-05
JP2017014264A (ja) 2017-01-19
JP6177975B2 (ja) 2017-08-09
UA111098C2 (uk) 2016-03-25
CN103998063B (zh) 2016-09-21
TWI653051B (zh) 2019-03-11
MX350341B (es) 2017-09-04
PL3075395T3 (pl) 2018-04-30
TWI583396B (zh) 2017-05-21
AU2017203423B2 (en) 2019-01-31
DOP2014000078A (es) 2014-07-15
EP2773376B1 (en) 2016-01-13
IL258229A (en) 2018-06-28
DK3075395T3 (en) 2018-02-19
JOP20190001A1 (ar) 2017-06-16
HUE027333T2 (en) 2016-09-28
CA2854134A1 (en) 2013-05-10
EP3075395A1 (en) 2016-10-05
KR20180108892A (ko) 2018-10-04
WO2013064508A1 (en) 2013-05-10
PE20141219A1 (es) 2014-09-13
HUE036535T2 (hu) 2018-07-30
EA025631B1 (ru) 2017-01-30
EA201400528A1 (ru) 2014-10-30
JP2014532682A (ja) 2014-12-08
RS54623B1 (sr) 2016-08-31
CY1119897T1 (el) 2018-06-27
SG10201607516SA (en) 2016-10-28
PT3075395T (pt) 2018-02-13
MY173372A (en) 2020-01-21

Similar Documents

Publication Publication Date Title
US9649363B2 (en) Polyethylene glycol based prodrug of adrenomedullin and use thereof
HK1246147B (zh) 聚乙二醇基肾上腺髓质素前药及其用途
HK1197652B (en) Polyethylene glycol based prodrug of adrenomedullin and use thereof
HK1197652A (en) Polyethylene glycol based prodrug of adrenomedullin and use thereof
NZ714621B2 (en) Polyethylene glycol based prodrug of adrenomedullin and use thereof
NZ622997B2 (en) Polyethylene glycol based prodrug of adrenomedullin and use thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 5/062 (2006.01), A61K 9/00 (2006.01), A61K 38

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/10/2012, OBSERVADAS AS CONDICOES LEGAIS.

B25G Requested change of headquarter approved

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT (DE) ; BAYER INTELLECTUAL PROPERTY GMBH (DE)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2798 DE 20-08-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.